In light of the promising preclinical activity of A17pro in the oncogenic setting of KRAS mutant LAC, we note that previous studies based on the use of non‐specific SMIs (e.g., hydroxamates) or RNA interference‐based approaches (siRNA, shRNA) in NSCLC cell lines have suggested that ADAM17 may have anti‐cancer activity in lung cancer (Zhou et al, 2006; Baumgart et al, 2010; Lv et al, 2014; Sharma et al, 2016). This evidence concerns the gene KRAS and cancer.